CAR-NK疗法在急性髓系白血病中的应用研究进展

苏帅; 肖毅

doi:10.3971/j.issn.1000-8578.2026.25.0749

您当前的位置：

首页 >

文章列表页 >

CAR-NK疗法在急性髓系白血病中的应用研究进展

综述 | 更新时间：2026-11-05

- CAR-NK疗法在急性髓系白血病中的应用研究进展
- Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia
- 肿瘤防治研究 2026年53卷第4期页码：281-288
- 作者机构：
- 作者简介：
  
  苏帅，男，博士在读，主要从事血液病的基础与临床研究，ORCID: 0009-0000-3280-4036
  肖毅，男，博士，主任医师，主要从事血液病的基础与临床研究，E-mail: yixiao@tjh.tjmu.edu.cn，ORCID: 0000-0001-7274-6774
- 基金信息：
  
  国家自然科学基金（81873444，82070213，82370196）
- DOI：10.3971/j.issn.1000-8578.2026.25.0749
  中图分类号： R733.71
- 纸质出版：2026
- 稿件说明：
移动端阅览
苏帅, 肖毅. CAR-NK疗法在急性髓系白血病中的应用研究进展[J]. 肿瘤防治研究, 2026, 53(4): 281-288.

SU Shuai, XIAO Yi. Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia[J]. 2026, 53(4): 281-288.
苏帅, 肖毅. CAR-NK疗法在急性髓系白血病中的应用研究进展[J]. 肿瘤防治研究, 2026, 53(4): 281-288. DOI： 10.3971/j.issn.1000-8578.2026.25.0749.

SU Shuai, XIAO Yi. Research Advances in Application of CAR-NK Therapy for Acute Myeloid Leukemia[J]. 2026, 53(4): 281-288. DOI： 10.3971/j.issn.1000-8578.2026.25.0749.

摘要

嵌合抗原受体T细胞（CAR-T）免疫疗法在B系血液系统肿瘤中已取得突破性进展，然而在急性髓系白血病（AML）中，因缺乏高度特异的肿瘤抗原，且部分靶点在正常造血干/祖细胞上同样表达，其疗效与可控性受限，因此可能出现显著的骨髓抑制及细胞因子释放综合征（CRS）等不良反应。相较之下，CAR-NK细胞免疫疗法作为一种新兴策略，依托NK细胞的天然抗肿瘤活性，表现出较低的CRS与移植物抗宿主病（GVHD）风险，早期临床研究亦提示其具有良好的安全性与抗肿瘤活性。本文聚焦CAR-NK疗法在AML治疗中的最新进展，并对未来发展趋势与潜在突破方向加以展望。

Abstract

Chimeric antigen receptor (CAR) T-cell therapy for B-cell hematologic malignancies has achieved breakthrough success; however

its efficacy for acute myeloid leukemia (AML) is constrained by the lack of highly specific tumor antigens and the expression of shared targets on normal hematopoietic stem/progenitor cells

increasing the risk of on-target myelosuppression and cytokine release syndrome (CRS). By contrast

CAR-NK cell therapy

an emerging strategy that leverages the innate antitumor activity of natural killer cells

is associated with low rates of CRS and graft-versus-host disease. Early clinical studies also indicate its favorable safety profile with preliminary antileukemic activity. This review summarizes recent advances in CAR-NK therapy for AML and discusses future directions and potential avenues for clinical translation.

关键词

Keywords

references

Gill S, Tasian SK, Ruella M, et al . Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells[J ] . Blood, 2014, 123(15): 2343-2354.

Wei W, Yang D, Chen X, et al . Chimeric antigen receptor T-cell therapy for T-ALL and AML[J ] . Front Oncol, 2022, 12: 967754.

Liu E, Marin D, Banerjee P, et al . Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors[J ] . N Engl J Med, 2020, 382(6): 545-553.

Saadh MJ, Torabi Fard N, Hussein A, et al . Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML[J ] . J Cancer Res Clin Oncol, 2025, 151(6): 193.

Tang X, Yang L, Li Z, et al . First-in-man clinical tri al of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia[J ] . Am J Cancer Res, 2018, 8(6): 1083-1089.

Huang R, Wang X, Yan H, et al . Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase Ⅰ trial[J ] . Exp Hematol Oncol, 2025, 14(1): 1.

Sauter CS, Borthakur G, Mountjoy L, et al . A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia[J ] . Blood, 2023, 142(Supplement 1): 2097.

Huang R, Li X, He Y, et al . Recent advances in CAR-T cell engineering[J ] . J Hematol Oncol, 2020, 13(1): 86.

Garrison B, Deng H, Yucel G, et al . Senti-202, a Selective, Off-the-Shelf, Preclinical CAR-NK Cell Therapy with CD33 and/or FLT3 Activating CAR, Healthy Cell Protection from Endomucin (EMCN) Inhibitory CAR and Calibrated Release IL-15 for Hematologic Malignancies Including AML[J ] . Blood, 2022, 140(Supplement 1): 4531-4532.

Perriello VM, Gionfriddo I, Rossi R, et al . CD123 Is Consistently Expressed on NPM1-Mutated AML Cells[J ] . Cancers (Basel), 2021, 13(3): 496.

Testa U, Riccioni R, Militi S, et al . Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis[J ] . Blood, 2002, 100(8): 2980-2988.

Fiorenza S, Turtle CJ. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success[J]. BioDrugs, 2021, 35(3): 281-302.

Caruso S, De Angelis B, Del Bufalo F, et al . Safe and effective off-the-shelf immunotherapy based on CAR. CD123-NK cells for the treatment of acute myeloid leukaemia[J ] . J Hematol Oncol, 2022, 15(1): 163.

Rahnama R, Kizerwetter M, Yang H, et al . Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality[J ] . J Immunother Cancer, 2025, 13(2): e010763.

Christodoulou I, Ho WJ, Marple A, et al . Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities[J ] . J Immunother Cancer, 2021, 9(12): e003894.

Soleimani Samarkhazan H, Zeht abcheh S, Seraji HR, et al . Unveiling the potential of CLL-1: a promising target for AML therapy[J ] . Biomark Res, 2025, 13(1): 28.

Zhang H, Bu C, Peng Z, et al . Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis[J ] . Leukemia, 2022, 36(11): 2596-2604.

Jin X, Zhang M, Sun R, et al . First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia[J ] . J Hematol Oncol, 2022, 15(1): 88.

Sedloev DN, Chen Q, Unglaub JM, et al . Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity[J ] . Blood, 2024, 144 (Supplement 1): 3440.

Shi Y, Hao D, Qian H, et al . Natural killer cell-based cancer immunotherapy: from basics to clinical trials[J ] . Exp Hematol Oncol, 2024, 13(1): 101.

Kumar S, Mahendiran S, Nair RS, et al . A mechanistic, functional, and clinical perspective on targeting CD70 in cancer[J ] . Cancer Lett, 2024, 611: 217428.

Flieswasser T, Van Den Eynde A, Van Audenaerde J, et al . The CD70-CD27 axis in oncology: the new kids on the block[J ] . J Exp Clin Cancer Res, 2022, 41(1): 12.

Sauer T, Parikh K, Sharma S, et al . CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity[J ] . Blood, 2021, 138(4): 318-330.

Wang L, Wang Y, He X, et al . CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells[J ] . Cell Rep Med, 2025, 6(1): 101889.

Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor[J]. Nat Rev Immunol, 2020, 20(3): 173-185.

Brunner AM, Esteve J, Porkka K, et al . Phase Ⅰb study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes[J ] . Am J Hematol, 2024, 99(2): E32-E36.

Klaihmon P, Samart P, Rojanasakul Y, et al . Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion[J ] . Exp Hematol Oncol, 2024, 13(1): 67.

Klaihmon P, Luanpitpong S, Kang X, et al . Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells[J ] . Cancer Cell Int, 2023, 23(1): 297.

Gurney M, Stikvoort A, Nolan E, et al . CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide[J ] . Haematologica, 2022, 107(2): 437-445.

Lin Y, Xiao Z, Hu F, et al . Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies[J ] . J Hematol Oncol, 2025, 18(1): 57.

Ran GH, Lin YQ, Tian L, et al . Natural killer cell homing and trafficking in tissues and tumors: from biology to application[J ] . Signal Transduct Target Ther, 2022, 7(1): 205.

He X, Wang L, Zeng W, et al . Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor[J ] . Trends Biotechnol, 2025, 43(7): 1668-1689.

Ladikou EE, Chevassut T, Pepper CJ, et al . Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia[J ] . Br J Haematol, 2020, 189(5): 815-825.

Liu F, Tarannum M, Zhao Y, et al . One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses[J ] . Blood, 2024, 144(Supplement 1): 915.

Wang H, Feng S, Zhu Y, et al . The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia[J ] . Blood Transfus, 2025, 23(4): 338-347.

Xie J, Liu XF, Zhou T, et al . Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia[J ] . Signal Transduct Target Ther, 2025, 10(1): 143.

Carter JL, Hege K, Yang J, et al . Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy[J ] . Signal Transduct Target Ther, 2020, 5(1): 288.

D'silva SZ, Singh M, Pinto AS. NK cell defects: implication in acute myeloid leukemia[J]. Front Immunol, 2023, 14: 1112059.

Yang K, Zhao Y, Sun G, et al . Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy[J ] . Front Immunol, 2022, 13: 1081546.

Zhu H, Blum RH, Bernareggi D, et al . Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity[J ] . Cell Stem Cell, 2020, 27(2): 224-237. e6.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肿瘤相关巨噬细胞在食管鳞癌中的作用机制及靶向治疗前景

多维免疫调控因子ZG16增强抗肿瘤免疫应答研究进展

肠道微生态特征与晚期MSS型消化道肿瘤免疫治疗疗效的相关性

免疫治疗时代下炎症营养指标对鼻咽癌的预后预测价值研究进展

CKIP-1在肿瘤免疫微环境中的功能及其作用机制研究进展